|Articles|August 9, 2016
Evidera to Join PPD
PPD announces the acquisition of Evidera, an evidence-based solutions provider.
Advertisement
PPD announces the acquisition of Evidera, an evidence-based solutions provider. As a subsidiary of PPD, Evidera will be deliver peri- and post-approval studies, health economics, outcomes research, epidemiology and market access consulting.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient OutcomesSeptember 17th 2025
Managing Background Therapies in the NIMBLE Phase III TrialSeptember 17th 2025
Generative AI Transforms Clinical Study Report DevelopmentSeptember 16th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success
2
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
3
Generative AI Transforms Clinical Study Report Development
4
Phase IV Trial Shows Strong Immune Response from Moderna’s Updated Spikevax Against LP.8.1 Variant of COVID-19
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
